Lemzoparlimab is a humanized anti-CD47 IgG4 monoclonal antibody with potent anti-tumor activity; it promotes macrophage-mediated phagocytosis and anti-tumor efficacy while minimizing binding to red blood cells to reduce hematologic toxicity such as anemia.